Elena Campione
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elena Campione has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Claudia Paganini
Department of Systems Medicine University of Rome “Tor Vergata” Rome Italy
1 shared publication - Cosimo Di Raimondo
Dermatology Unit, Fondazione Policlinico “Tor Vergata”, 00133 Rome, Italy
1 shared publication - Flavia Lozzi
Department of Dermatology, University of Roma Tor Vergata, 00133 Rome, Italy
1 shared publication - Luca Bianchi
Department of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy
1 shared publication - Marco Galluzzo
Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
1 shared publication - Pier Paolo Di Domenico
Department of Systems Medicine, University of Rome “Tor Vergata”, 00133 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 28 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7099
Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells. Although disease awareness has increased over time, BPDCN represents a rare disease with an aggressive clinical course and a dismal prognosis. Due to the overlap in clinical and histological features with a large spectrum of inflammatory and neoplastic diseases, BPDCN is difficult to diagnose. Furthermore, given the rarity of the disease, treatment options for BPDCN are limited, sometimes changing by practitioner and hospitals. Treatment options range from conventional chemotherapy to the recently approved biologic agent tagraxofusp and stem cell transplantation. Therefore, a multidisciplinary approach with coordination among dermatologists, pathologists, and hematologists is ultimately imperative to reach the correct diagnosis and management of BPDCN.
- 28 June 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (13) , 7099
Open AccessBlastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematological malignancy derived from the precursors of plasmacytoid dendritic cells. Although disease awareness has increased over time, BPDCN represents a rare disease with an aggressive clinical course and a dismal prognosis. Due to the overlap in clinical and histological features with a large spectrum of inflammatory and neoplastic diseases, BPDCN is difficult to diagnose. Furthermore, given the rarity of the disease, treatment options for BPDCN are limited, sometimes changing by practitioner and hospitals. Treatment options range from conventional chemotherapy to the recently approved biologic agent tagraxofusp and stem cell transplantation. Therefore, a multidisciplinary approach with coordination among dermatologists, pathologists, and hematologists is ultimately imperative to reach the correct diagnosis and management of BPDCN.